Antonina Minniti

Dr. Antonina Minniti

ASST Gaetano Pini Cto, Milan, Lombardy, Italy
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
NPNicoletta Del Papa
Nicoletta Del Papa
AMAntonina Minniti
Antonina Minniti
MLMaurizio Lorini
Maurizio Lorini
VCVincenzo Carbonelli
Vincenzo Carbonelli
WMWanda Maglione
Wanda Maglione
CVClaudio Vitali
Claudio Vitali
There is a great deal of evidence pointing to interferons (IFNs) as being key cytokines in the pathogenesis of different systemic autoimmune diseases, including primary Sjögren’s syndrome (pSS). In this disease, a large number of studies have shown that an overexpression of type I IFN, the ‘so-called’ type I IFN signature, is present in peripheral blood mononuclear cells, and that this finding is associated with the development of systemic extra-glandular manifestations, and a substantial production of autoantibodies and inflammatory cytokines. In contrast, the absence or a milder expression of type I IFN signature and low level of inflammatory cytokines characterizes patients with a different clinical phenotype, where the disease is limited to glandular involvement and often marked by the presence of widespread pain and depression. The role of type II (IFNγ) in this subset of pSS patients, together with the potentially related activation of completely different immunological and metabolic pathways, are emerging issues. Expression of both types of IFNs has also been shown in target tissues, namely in minor salivary glands where a predominance of type II IFN signature appeared to have a certain association with the development of lymphoma. In view of the role played by IFN overexpression in the development and progression of pSS, inhibition or modulation of IFN signaling has been regarded as a potential target for the therapeutic approach. A number of therapeutic compounds with variable mechanisms of action have been tested or are under consideration for the treatment of patients with pSS.

24 October 2022 in Cells
Verified
Journal Article
Open access
PDF file
EXElisabetta Xue
Elisabetta Xue
AMAntonina Minniti
Antonina Minniti
TATobias Alexander
Tobias Alexander
NPNicoletta Del Papa
Nicoletta Del Papa
RGRaffaella Greco
Raffaella Greco
HYHui Yao
Hui Yao
Systemic sclerosis (SSc) is a systemic disease characterized by autoimmune responses, vasculopathy and tissue fibrosis. The pathogenic mechanisms involve a wide range of cells and soluble factors. The complexity of interactions leads to heterogeneous clinical features in terms of the extent, severity, and rate of progression of skin fibrosis and internal organ involvement. Available disease-modifying drugs have only modest effects on halting disease progression and may be associated with significant side effects. Therefore, cellular therapies have been developed aiming at the restoration of immunologic self-tolerance in order to provide durable remissions or to foster tissue regeneration. Currently, SSc is recommended as the ‘standard indication’ for autologous hematopoietic stem cell transplantation by the European Society for Blood and Marrow Transplantation. This review provides an overview on cellular therapies in SSc, from pre-clinical models to clinical applications, opening towards more advanced cellular therapies, such as mesenchymal stem cells, regulatory T cells and potentially CAR-T-cell therapies.

1 January 2020 in Therapeutic Advances in Musculoskeletal Disease
Verified
Journal Article
Open access
PDF file
NPNicoletta Del Papa
Nicoletta Del Papa
Gianluca SambataroGianluca Sambataro
Gianluca Sambataro
AMAntonina Minniti
Antonina Minniti
WMWanda Maglione
Wanda Maglione
FPFrancesca Pignataro
Francesca Pignataro
RCRoberto Caporali
Roberto Caporali
Background: Mortality rate in patients infected by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can be related to the presence of comorbidities like diabetes, cardiovascular and pulmonary diseases. On the contrary, few data exist on the impact of CoronaVirus Disease 2019 (COVID-19) on patients with rheumatic disorders, namely in those having pulmonary involvement and treated with immunosuppressive agents. The present survey is aimed at knowing the impact of COVID-19 in a cohort of patients with systemic sclerosis (SSc). Methods: Telephone interviews were carried out during the COVID-19 outbreak in patients with SSc followed in a Rheumatic Disease Unit in Italy. Patients were asked for confirmed SARS-CoV-2 infection, symptoms suggestive of COVID-19, and modification of their therapy. Results: A total number of 526 patients with SSc were contacted and interviewed. Of them, 270 and 256 had limited cutaneous and diffuse cutaneous SSc, respectively. Interstitial lung disease (ILD) was present in 45% of patients and most of them (68.2%) were treated with immunosuppressive therapy. Only two patients were hospitalized for COVID-19-related pneumonia, and one of them died despite invasive ventilator support. An additional 11 patients reported flu-like symptoms compatible with a mild form of COVID-19. Nobody modified the therapy during the COVID-19 outbreak. Conclusion: Despite the large prevalence of ILD and immunosuppressive therapies, which can be considered risk factors for the occurrence and severity of incidental viral infections, the impact of COVID-19, in terms of mortality rate and morbidity, does not appear particularly severe in this large cohort of patients with SSc. Possible mechanisms influencing this figure are discussed.

28 June 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
NPNicoletta Del Papa
Nicoletta Del Papa
AMAntonina Minniti
Antonina Minniti
WMWanda Maglione
Wanda Maglione
FPFrancesca Pignataro
Francesca Pignataro
RCRoberto Caporali
Roberto Caporali
CVClaudio Vitali
Claudio Vitali
Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disorder characterized by very heterogeneous features. The spectrum of this disorder may vary from benign but disabling symptoms such as dryness, due to lachrymal and salivary involvement, pain and fatigue, to systemic, potentially severe, manifestations that may involve any organ. In recent decades, the arrival of biotechnological therapy has offered new opportunities for the treatment of this—until now—orphan disease. Currently, the possible use of these new drugs in therapeutic trials has made it necessary to have reliable outcome measures to evaluate their efficacy in this disease. A great effort has been made in multicenter, often multinational, studies to develop and validate instruments capable of assessing the different disease-related features. The adoption in therapeutic trials of the newly developed outcome measures aimed at assessing systemic features and patient reported symptoms has often yielded disappointing results. These negative data have been ascribed, on the one hand, to the trial design not being completely appropriate, and, on the other hand, to the fact that a single instrument may be not sufficient to cover the great clinical heterogeneity of the disease features. There is now growing belief that composite end points that include instruments that are able to assess the various aspects of the disease may be more properly and successfully used in future therapeutic trials.

4 April 2026 in Rheumatology
Verified
Journal Article
Closed access
PDF file
MPMaria Rosa Pellico
Maria Rosa Pellico
CBCristina Bochicchio
Cristina Bochicchio
EMElisabetta Miserocchi
Elisabetta Miserocchi
SCSilvia Cavalli
Silvia Cavalli
IMIlaria Magi
Ilaria Magi
NPNicoletta Del Papa
Nicoletta Del Papa
The 2023 International Myositis Assessment and Clinical Studies Group (IMACS) guidelines introduced a standardized risk-stratification model for cancer screening in idiopathic inflammatory myopathies (IIM). However, real-world data on their application remain limited. This study aimed to evaluate the effectiveness of IMACS-based risk stratification in predicting malignancy and assess adherence to cancer screening recommendations in a multicentric Italian IIM cohort. We conducted a multicentre retrospective study including 411 IIM patients from five Italian rheumatology centres, classified into IMACS-defined standard, intermediate, and high-risk groups. Cancer occurrence within three years of IIM diagnosis was assessed. Screening practices prior to the implementation of IMACS guidelines were compared with their recommendations. Logistic regression analysis was used to evaluate the predictive value of IMACS stratification. Among 411 patients, 180 (43.8%) were classified as high-risk, 156 (37.7%) as intermediate-risk, and 75 (18.2%) as standard-risk. Cancer was diagnosed in 9.2% of patients within three years of IIM onset, with high-risk patients significantly more likely to develop malignancy (OR = 4.05, p= 0.026). Anti-TIF1γ (OR = 12.3, p< 0.001) and anti-SAE1 (OR = 11.9, p= 0.012) were independent predictors of cancer. Screening adherence varied, with underutilization of enhanced screening in intermediate-risk patients and a decline in screening over time. The IMACS stratification model effectively predicts cancer risk in IIM. However, real-world screening practices show inconsistencies, particularly in intermediate-risk patients. These findings support the need for optimized, risk-adapted malignancy surveillance in IIM and refinement of current guidelines based on real-world data.

1 June 2020 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
NPNicoletta Del Papa
Nicoletta Del Papa
MLM. Lorini
M. Lorini
VCV. Carbonelli
V. Carbonelli
AMAntonina Minniti
Antonina Minniti
FPF. Pignataro
F. Pignataro
RCRoberto Caporali
Roberto Caporali
Background: Adipose-derived stromal/stem cells (ADSCs) are multipotential non-hematopoietic progenitor cells with anti-inflammatory, immunomodulatory and regenerative effects. They have the advantage of accessibility and potent pro-angiogenic effects when compared with other stem cells, such as bone-marrow derived stem cells. Recent studies have shown that autologous fat grafting may be effective in the treatment of fibrotic and vascular complications in systemic sclerosis (SSc), despite a pro-fibrotic signature. Objectives: Aim of the study was to better characterize the proliferative and secretive profile of ADSCs in normoxic and hypoxic conditions, and to evaluate the mechanisms by which ADSCs exert these observed clinical effects. Methods: Adipose tissue samples were obtained by liposuction from 12 SSc patients and 10 healthy donors (HD). ADSCs were purified according to their adherence to the plastic and characterized to express specific MSC surface antigens by flow cytometry analysis. Proliferation of ADSCs from SSc patients and normal controls was evaluated in normoxic and hypoxic conditions. Fibroblasts and ADSCs derived from SSc patients were co-cultured in direct and indirect culture systems and compared to HD. Fibroblasts proliferation, mRNA expression and protein secretion of VEGF and known fibrotic mediators including TGF β-1, TGFR, CTGF, Collagen type I (Col I) were analyzed in the same conditions. Results: Normoxic and hypoxic culture conditions did not modify the proliferation rate of both normal and SSc ADSCs. Hypoxia significantly increased mRNA expression of VEGF by HD and SSc ADSCs but had no effect on the mRNA expression of pro-fibrotic mediators, ie TGFβ and TGFR. Normal and SSc fibroblast proliferation was significantly reduced in both co-culture systems (p < 0.001) and by treatment with normoxic and hypoxic conditioned medium (CM) (p=0.001 and p=0.002). In the same conditions, mRNA expression and protein secretion of TGF-β1, CTGF and Col I were significantly reduced (p = 0.003, p =0.02, p=0.04). These results were confirmed when normal and SSc fibroblasts were cultured in the presence of ADSCs normoxic and hypoxic CM (p=0.02 and p=0.01). Furthermore, a significant increase in mRNA expression and production of VEGF was observed in SSc fibroblasts cultured in the presence of normoxic and hypoxic CM (p = 0.002 and p< 0.0001, respectively). Conclusion: We found that treatment with the medium from normoxic and hypoxic preconditioned ADSCs has an anti-fibrotic effect through both the inhibition of fibroblast proliferation and key mediators of fibrosis. The increased expression of VEGF by SSc fibroblasts in the presence of normoxic and, even more, hypoxic ADSCs CM, suggests that ADSCs can induce a paracrine pro-angiogenic phenotype, even in fibroblasts with a pro-fibrotic signature. Altogether these data show that ADSCs may exert their anti-fibrotic and pro-angiogenetic effects on SSc fibroblasts by the secretion of paracrine factors, partly explaining the mechanisms underlining beneficial clinical results of fat graft in SSc patients. Disclosure of Interests: Nicoletta Del Papa: None declared, Maurizio Lorini: None declared, Vincenzo Carbonelli: None declared, Antonina Minniti: None declared, Francesca Pignataro: None declared, Wanda Maglione: None declared, Gabriele Di Luca: None declared, Nicola Montano: None declared, Roberto Caporali Consultant of: AbbVie; Gilead Sciences, Inc.; Lilly; Merck Sharp & Dohme; Celgene; Bristol-Myers Squibb; Pfizer; UCB, Speakers bureau: Abbvie; Bristol-Myers Squibb; Celgene; Lilly; Gilead Sciences, Inc; MSD; Pfizer; Roche; UCB